BBA Advances Biochemistry

Structural modification of 5-alkyl-4-phenyl-thiazole-based fatty acid amide hydrolase and soluble epoxide hydrolase inhibitors to alleviate orofacial inflammatory pain in the rat

Gabrielle Gorostiza, Madison Mercado, Lucy Pavana, Daniel Carr, Cassandra Yuan, Amanda Tsang, Karen Gomez, Ian Minton, Dylan Carrillo, Manuel Berumen, Stevan Pecic, Ram Kandasamy
Elsevier · · DOI 10.2139/ssrn.6352721

Abstract

Orofacial pain conditions are prevalent and difficult to manage, as existing treatments such as opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and serotonin agonists often provide limited relief or produce disruptive side effects. These limitations highlight the need for alternative strategies that reduce orofacial inflammatory pain without adverse effects. One approach is polypharmacology by design, where a single compound modulates multiple biological targets involved in pain and inflammation. Fatty acid amide hydrolase (FAAH) and soluble epoxide hydrolase (sEH) are key regulators of pain signaling that can be targeted simultaneously to enhance antinociceptive efficacy. We previously reported that the 4-phenylthiazole-based dual FAAH/sEH inhibitor SW-17 does not alleviate acute orofacial inflammatory pain in rats. In this study, we introduced electronic and steric modifications to the thiazole and phenyl rings of the 4-phenylthiazole scaffold. An 11-compound library was synthesized by varying alkyl groups at position 5 of the thiazole ring and substituents on the phenyl ring. Several analogs exhibited nanomolar potency at both enzymes. The most potent compound, 4j, exhibited IC50 values of 18.7 nM and 25.1 nM for human FAAH and sEH, respectively. ADMET studies indicated that 4j possesses promising safety features for in vivo testing. At 3 mg/kg, 4jreversed acute orofacial inflammatory pain, whereas lower doses and SW-17 were ineffective. The antinociceptive effect was comparable to sumatriptan and did not reduce voluntary wheel running, suggesting a lack of motor side effects. These findings demonstrate that optimized dual FAAH/sEH inhibitors can alleviate acute orofacial pain without affecting normal behavior.

Read at publisher →